Editors’ Picks: January 2024 Highlights from the AACR Journals
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
Progress Against Cancer
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug discovery.
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts on precision medicine.
January is Cervical Cancer Awareness Month. Here's the latest on prevention, screening, and treatment.
Metastatic breast cancer remains incurable, but researchers’ understanding of the molecular features of the disease is leading to additional treatments.
Researchers are looking at ways to lessen and even prevent the debilitating chemotherapy-related side effect that causes numbness and pain in the hands and feet.
Study suggests people with advanced lung cancer who have a sustained response to immunotherapy can safely stop treatment after two years.
Study supports the use of immune checkpoint inhibitors in an understudied population.
An implantable device, along with an infusion of microbubbles, helps increase chemotherapy concentrations for brain cancer.
Some women with early-stage cervical cancer may be able to receive simple hysterectomy, which reduces the risk of complications.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More